Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 31, 2007

Laureate to Manufacture Enobia Pharma’s Candidate against Hypophosphatasia

  • Laureate Pharma entered into a cGMP contract manufacturing agreement with Enobia Pharma, which is engaged in the development of enzyme replacement therapy for the treatment of hypophosphatasia.

    Laureate will produce Enobia Pharma’s fusion protein for this rare and sometimes fatal metabolic bone disease characterized by skeletal hypomineralization. Enobia anticipates initiating clinical studies in this lead program  in the summer of 2008.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »